文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-HER2-affibody PET/CT无创评估尿路上皮癌HER2表达与异质性

Noninvasive Evaluation of HER2 Expression and Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT.
PubMed 文献 · Clin Nucl Med · 2025-12-08

HER2阳性者68Ga-HER2-affibody PET/CT的SUVmax、SUVmean、TMR及HER2-TV显著更高,HER2-SUVmax与TMR鉴别HER2状态的AUC分别为0.87和0.88;患者内病灶SUVmax变异系数中位数49.7%。

要点

  • 68Ga-HER2-affibody PET/CT可无创区分尿路上皮癌HER2阳性与阴性。
  • HER2-SUVmax与TMR对HER2状态有较强预测价值,AUC分别为0.87和0.88。
  • 患者内转移灶HER2摄取异质性高,SUVmax变异系数中位数49.7%。

核心结论

  • 68Ga-HER2-affibody PET/CT是無创检测尿路上皮癌HER2状态与异质性的可行方法,有助于筛选HER2靶向治疗获益人群。

主要发现

  • HER2阳性患者68Ga-HER2-affibody PET/CT的SUVmax、SUVmean、TMR及HER2-TV均显著高于HER2阴性患者(均P<0.05)。
  • 18F-FDG PET/CT除MTV和TLG外(P<0.05),其余参数在HER2状态间无显著差异。
  • HER2-PET/CT参数随HER2免疫组化状态呈阶梯式升高(Ptrend<0.05)。
  • 患者内转移灶HER2摄取异质性高,SUVmax变异系数中位数49.7%(IQR:29.7%-64%)。

关键数值与推荐

  • ROC分析显示HER2-SUVmax鉴别HER2阴性/阳性的AUC为0.87,TMR的AUC为0.88。
  • 7例接受HER2靶向治疗患者中,2例PET/CT低摄取者出现疾病进展,5例高摄取者中4例达部分缓解。

临床怎么用

  • 可用于尿路上皮癌HER2状态的无创评估,辅助筛选HER2靶向治疗候选者。
  • 需关注患者内病灶间HER2摄取的异质性,避免单一病灶取样偏差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Human epidermal growth factor receptor 2 (HER2) is a promising therapeutic target in urothelial carcinoma (UC). We aimed to evaluate the feasibility of 68Ga-HER2 affibody PET/CT in assessing HER2 expression and tumor heterogeneity, and to explore its utility for guiding HER2-targeted therapy in UC. PATIENTS AND METHODS: Thirty-two patients with UC who underwent 68Ga-HER2-affibody and 18F-FDG-PET/CT were prospectively recruited from September 2024 to April 2025. Semiquantitative PET/CT parameters (SUVmax, SUVmean, TMR, HER2-TV/MTV, and TL-HER2/TLG) were analyzed across HER2 statuses. Intrapatient heterogeneity of SUVmax across lesions was assessed by the coefficient of variation (CV). RESULTS: HER2-positive patients demonstrated significantly higher SUVmax, SUVmean, TMR, and HER2-TV of 68Ga-HER2-affibody PET/CT compared with HER2-negative patients (all P < 0.05). No significant differences were observed in 18F-FDG PET/CT except for MTV and TLG (P < 0.05). ROC analysis revealed strong predictive value for HER2-SUVmax (AUC: 0.87) and TMR (AUC: 0.88) in differentiating HER2-negative/positive. Stepwise increases in HER2-PET/CT parameters were observed across HER2 immunohistochemistry statuses (Ptrend < 0.05). HER2-PET/CT demonstrated high heterogeneity, with a median SUVmax CV of 49.7% (IQR: 29.7%-64%) across intrapatient metastatic lesions. In 7 patients receiving HER2-target therapy, 2 patients with low HER2 uptake on PET/CT developed progressive disease, whereas 4 of 5 patients with high uptake achieved a partial response. CONCLUSIONS: 68Ga-HER2 affibody PET/CT is a feasible method to detect the HER2 status and heterogeneity in UC patients noninvasively. This method provides a valuable tool for identifying patients who benefit from HER2-target therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tao Z, Chen X, Tang Q, et al. Noninvasive Evaluation of HER2 Expression and Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT. Clin Nucl Med. 2025. PMID: 41499308. doi:10.1097/RLU.0000000000006239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。